Patents by Inventor Ju-Gyeong Kang

Ju-Gyeong Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for assessing atherosclerosis by measuring expression of FOS or DUSP1 in monocytes
    Patent number: 7998682
    Abstract: A non-invasive method for the diagnosis of atherosclerosis is provided. In one example, the method includes assaying the expression of FOS, DUSP1, or both FOS and DUSP1 in monocytes or a cell fraction thereof, or in plasma, serum or peripheral blood from the subject. An increase the expression of FOS, DUSP1, or both FOS and DUSP1 in monocytes in the sample as compared to a control indicates that the subject has atherosclerosis. A method is also provided for determining if a pharmaceutical agent is effective for treatment of atherosclerosis in a subject. The method includes assaying the expression of FOS, DUSP1, or both FOS and DUSP1 in a monocytes treated with the pharmaceutical agent, wherein a decrease the expression of FOS, DUSP1, or both FOS and DUSP1 in monocytes in the sample as compared to a control indicates that the pharmaceutical agent is effective for the treatment of atherosclerosis. The monocytes can be contacted with the agent in vivo or in vitro.
    Type: Grant
    Filed: September 2, 2005
    Date of Patent: August 16, 2011
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Paul M. Hwang, Willmar D. Patino, Omar Y. Mian, Ju-Gyeong Kang, Satoaki Matoba
  • Method for Assessing Atherosclerosis
    Publication number: 20070258902
    Abstract: A non-invasive method for the diagnosis of atherosclerosis is provided. In one example, the method includes assaying the expression of FOS, DUSP1, or both FOS and DUSP1 in monocytes or a cell fraction thereof, or in plasma, serum or blood from the subject, wherein an increase the expression of FOS, DUSP1, or both FOS and DUSP1 in monocytes in the sample as compared to a control indicates that the subject has atherosclerosis. In one example, the monocytes are in a peripheral blood sample. A method is also provided for determining if a pharmaceutical agent is effective for treatment of atherosclerosis in a subject. The method includes assaying the expression of FOS, DUSP1, or both FOS and DUSP1 in a monocytes treated with the pharmaceutical agent, wherein a decrease the expression of FOS, DUSP1, or both FOS and DUSP1 in monocytes in the sample as compared to a control indicates that the pharmaceutical agent is effective for the treatment of atherosclerosis.
    Type: Application
    Filed: September 2, 2005
    Publication date: November 8, 2007
    Inventors: Paul Hwang, Willmar Patino, Omar Mian, Ju-Gyeong Kang, Satoaki Matoba